China Shineway Pharmaceutical Group Limited (HKG: 2877)
Hong Kong
· Delayed Price · Currency is HKD
8.65
-0.46 (-5.05%)
Jan 3, 2025, 4:08 PM HKT
China Shineway Pharmaceutical Group Revenue
China Shineway Pharmaceutical Group had revenue of 2.09B CNY in the half year ending June 30, 2024, with 14.96% growth. This brings the company's revenue in the last twelve months to 4.20B, down -7.27% year-over-year. In the year 2023, China Shineway Pharmaceutical Group had annual revenue of 4.52B with 14.32% growth.
Revenue (ttm)
4.20B CNY
Revenue Growth
-7.27%
P/S Ratio
1.45
Revenue / Employee
1.22M CNY
Employees
3,436
Market Cap
6.53B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4.52B | 565.90M | 14.32% |
Dec 31, 2022 | 3.95B | 727.09M | 22.56% |
Dec 31, 2021 | 3.22B | 567.85M | 21.38% |
Dec 31, 2020 | 2.66B | -50.30M | -1.86% |
Dec 31, 2019 | 2.71B | 135.80M | 5.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 26.04B |
Hansoh Pharmaceutical Group Company | 13.00B |
JD Health International | 58.84B |
WuXi Biologics | 18.39B |
Sinopharm Group | 634.32B |
Innovent Biologics | 8.01B |
Sino Biopharmaceutical | 29.86B |
CSPC Pharmaceutical Group | 33.53B |